1.
Nikkola E, Ko A, Alvarez M, et al. Family-specific aggregation of lipid GWAS variants confers the susceptibility to familial hypercholesterolemia in a large Austrian family. Atherosclerosis. 2017;264:58-66. doi:10.1016/j.atherosclerosis.2017.07.024.
1.
Alver M, Palover M, Saar A, et al. Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia. Genet Med. 2019;21(5):1173-1180. doi:10.1038/s41436-018-0311-2.
1.
Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing. Circulation. 2017;136(23):2210-2219. doi:10.1161/CIRCULATIONAHA.117.028430.